BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 28012402)

  • 1. Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data.
    Giuffrida FMA; Moises RS; Weinert LS; Calliari LE; Manna TD; Dotto RP; Franco LF; Caetano LA; Teles MG; Lima RA; Alves C; Dib SA; Silveiro SP; Dias-da-Silva MR; Reis AF;
    Diabetes Res Clin Pract; 2017 Jan; 123():134-142. PubMed ID: 28012402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
    Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
    Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three unreported glucokinase (GCK) missense mutations detected in the screening of thirty-two Brazilian kindreds for GCK and HNF1A-MODY.
    Weinert LS; Silveiro SP; Giuffrida FM; Cunha VT; Bulcão C; Calliari LE; Della Manna T; Kunii IS; Dotto RP; Dias-da-Silva MR; Reis AF
    Diabetes Res Clin Pract; 2014 Nov; 106(2):e44-8. PubMed ID: 25174781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
    López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
    Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of ACMG-AMP guidelines in HNF1A and GCK variants in a cohort of MODY families.
    Santana LS; Caetano LA; Costa-Riquetto AD; Quedas EPS; Nery M; Collett-Solberg P; Boguszewski MCS; Vendramini MF; Crisostomo LG; Floh FO; Zarabia ZI; Kohara SK; Guastapaglia L; Passone CGB; Sewaybricker LE; Jorge AAL; Teles MG
    Clin Genet; 2017 Oct; 92(4):388-396. PubMed ID: 28170077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MODY probability calculator for GCK and HNF1A screening in a multiethnic background population.
    Tarantino RM; Abreu GM; Fonseca ACP; Kupfer R; Pereira MFC; Campos Júnior M; Zajdenverg L; Rodacki M
    Arch Endocrinol Metab; 2020 Feb; 64(1):17-23. PubMed ID: 31576961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
    Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
    Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
    Ellard S; Colclough K
    Hum Mutat; 2006 Sep; 27(9):854-69. PubMed ID: 16917892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
    Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
    Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.
    Liu J; Xiao X; Zhang Q; Yu M
    J Diabetes; 2023 Jun; 15(6):519-531. PubMed ID: 37226652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maturity onset diabetes of the young (MODY) in Chinese children: genes and clinical phenotypes.
    Ming-Qiang Z; Yang-Li D; Ke H; Wei W; Jun-Fen F; Chao-Chun Z; Guan-Ping D
    J Pediatr Endocrinol Metab; 2019 Jul; 32(7):759-765. PubMed ID: 31216263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maturity onset diabetes of the young due to
    Pavić T; Juszczak A; Pape Medvidović E; Burrows C; Šekerija M; Bennett AJ; Ćuća Knežević J; Gloyn AL; Lauc G; McCarthy MI; Gornik O; Owen KR
    Biochem Med (Zagreb); 2018 Jun; 28(2):020703. PubMed ID: 29666556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and genetic characterization and long-term evaluation of individuals with maturity-onset diabetes of the young (MODY): The journey towards appropriate treatment.
    Campos Franco P; Santos de Santana L; Dantas Costa-Riquetto A; Santomauro Junior AC; Jorge AAL; Gurgel Teles M
    Diabetes Res Clin Pract; 2022 May; 187():109875. PubMed ID: 35472491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
    Ozsu E; Cizmecioglu FM; Yesiltepe Mutlu G; Yuksel AB; Calıskan M; Yesilyurt A; Hatun S
    Horm Res Paediatr; 2018; 90(4):257-265. PubMed ID: 30481753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HNF1alpha mutations are present in half of clinically defined MODY patients in South-Brazilian individuals.
    Maraschin Jde F; Kannengiesser C; Murussi N; Campagnolo N; Canani LH; Gross JL; Velho G; Grandchamp B; Silveiro SP
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1326-31. PubMed ID: 19169489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.